|
Iris Oifigiúil |
GA Sraith C |
|
C/2024/6277 |
21.10.2024 |
Achoimre ar chinntí an Aontais Eorpaigh maidir le húdaruithe margaíochta i ndáil le táirgí íocshláinte ó 1 Meán Fómhair 2024 go dtí 30 Meán Fómhair 2024
(Arna fhoilsiú de bhun Airteagal 13 nó Airteagal 38 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle (1) nó Airteagal 5 de Rialachán (AE) 2019/6 ó Pharlaimint na hEorpa agus ón gComhairle (2) )
(C/2024/6277)
— Údarú margaíochta a eisiúint (Airteagal 13 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle): Glactha
|
Dáta an chinnidh |
Ainm an táirge íocshláinte |
ANI (an tAinm Neamhdhílseánaigh Idirnáisiúnta) |
Sealbhóir an údaraithe margaíochta |
Uimhir na hiontrála sa Chlár Comhphobail |
Foirm chógaisíochta |
An Cód CAT (an Cód Ceimiceach Teiripeach Anatamaíoch) |
Dáta an fhógra |
||
|
12.9.2024 |
Eksunbi |
ustekinumab |
|
EU/1/24/1858 |
Tiúchán do thuaslagán le haghaidh insilte Tuaslagán le haghaidh insteallta |
L04AC05 |
13.9.2024 |
||
|
19.9.2024 |
Anzupgo |
delgocitinib |
|
EU/1/24/1851 |
Cream |
D11AH11 |
23.9.2024 |
||
|
19.9.2024 |
Axitinib Accord |
axitinib |
|
EU/1/24/1847 |
Piolla brataithe le scannán |
L01EK01 |
23.9.2024 |
||
|
19.9.2024 |
Iqirvo |
elafibranor |
|
EU/1/24/1855 |
Piolla brataithe le scannán |
A05AX06 |
23.9.2024 |
||
|
19.9.2024 |
Ituxredi |
rítúxímab |
|
EU/1/24/1861 |
Tiúchán do thuaslagán le haghaidh insilte |
L01X C02 |
23.9.2024 |
||
|
19.9.2024 |
KAYFANDA |
N/A |
|
EU/1/24/1854 |
Capsúl, crua |
A05AX |
26.9.2024 |
||
|
19.9.2024 |
LOQTORZI |
toripalimab |
|
EU/1/24/1853 |
Tiúchán do thuaslagán le haghaidh insilte |
L01FF13 |
23.9.2024 |
||
|
19.9.2024 |
Ranibizumab Midas |
ranibizumab |
|
EU/1/24/1860 |
Tuaslagán le haghaidh insteallta |
S01LA04 |
24.9.2024 |
||
|
19.9.2024 |
Tuznue |
trastuzumab |
|
EU/1/24/1864 |
Púdar do thiúchán do thuaslagán le haghaidh insilte |
L01FD01 |
24.9.2024 |
||
|
19.9.2024 |
Vevizye |
ciclosporin |
|
EU/1/24/1857 |
Eye drops, solution |
S01XA18 |
23.9.2024 |
||
|
19.9.2024 |
Vyloy |
zolbetuximab |
|
EU/1/24/1856 |
Púdar do thiúchán do thuaslagán le haghaidh insilte |
L01FX31 |
25.9.2024 |
||
|
25.9.2024 |
Fymskina |
ustekinumab |
|
EU/1/24/1862 |
Tiúchán do thuaslagán le haghaidh insilte Tuaslagán le haghaidh insteallta |
L04AC05 |
26.9.2024 |
||
|
25.9.2024 |
Otulfi |
ustekinumab |
|
EU/1/24/1863 |
Tiúchán do thuaslagán le haghaidh insilte Tuaslagán le haghaidh insteallta |
L04AC05 |
26.9.2024 |
||
|
27.9.2024 |
Yuvanci |
Macitentan / Tadalafil |
|
EU/1/24/1859 |
Piolla brataithe le scannán |
C02KX54 |
30.9.2024 |
— Údarú margaíochta a mhodhnú (Airteagal 13 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle): Glactha
|
Dáta an chinnidh |
Ainm an táirge íocshláinte |
Sealbhóir an údaraithe margaíochta |
Uimhir na hiontrála sa Chlár Comhphobail |
Dáta an fhógra |
||
|
6.9.2024 |
Abseamed |
|
EU/1/07/412 |
17.9.2024 |
||
|
6.9.2024 |
Atectura Breezhaler |
|
EU/1/20/1439 |
9.9.2024 |
||
|
6.9.2024 |
Dabigatran etexilate Leon Farma |
|
EU/1/23/1769 |
17.9.2024 |
||
|
6.9.2024 |
Deferasirox Accord |
|
EU/1/19/1412 |
9.9.2024 |
||
|
6.9.2024 |
Docetaxel Kabi |
|
EU/1/12/770 |
10.9.2024 |
||
|
6.9.2024 |
Entresto |
|
EU/1/15/1058 |
9.9.2024 |
||
|
6.9.2024 |
Filgrastim Hexal |
|
EU/1/08/496 |
9.9.2024 |
||
|
6.9.2024 |
Gazyvaro |
|
EU/1/14/937 |
9.9.2024 |
||
|
6.9.2024 |
Grastofil |
|
EU/1/13/877 |
9.9.2024 |
||
|
6.9.2024 |
Palforzia |
|
EU/1/20/1495 |
13.9.2024 |
||
|
6.9.2024 |
Pritor |
|
EU/1/98/089 |
9.9.2024 |
||
|
6.9.2024 |
Rhokiinsa |
|
EU/1/19/1400 |
9.9.2024 |
||
|
6.9.2024 |
Riximyo |
|
EU/1/17/1184 |
9.9.2024 |
||
|
6.9.2024 |
Trumenba |
|
EU/1/17/1187 |
9.9.2024 |
||
|
6.9.2024 |
Zarzio |
|
EU/1/08/495 |
9.9.2024 |
||
|
6.9.2024 |
Zessly |
|
EU/1/18/1280 |
11.9.2024 |
||
|
6.9.2024 |
Ziagen |
|
EU/1/99/112 |
9.9.2024 |
||
|
6.9.2024 |
Zimbus Breezhaler |
|
EU/1/20/1440 |
9.9.2024 |
||
|
10.9.2024 |
Spikevax |
|
EU/1/20/1507 |
11.9.2024 |
||
|
12.9.2024 |
Kinzalmono |
|
EU/1/98/091 |
13.9.2024 |
||
|
12.9.2024 |
Micardis |
|
EU/1/98/090 |
16.9.2024 |
||
|
12.9.2024 |
Pelgraz |
|
EU/1/18/1313 |
13.9.2024 |
||
|
12.9.2024 |
Rukobia |
|
EU/1/20/1518 |
13.9.2024 |
||
|
12.9.2024 |
Xelevia |
|
EU/1/07/382 |
13.9.2024 |
||
|
16.9.2024 |
Adtralza |
|
EU/1/21/1554 |
19.9.2024 |
||
|
16.9.2024 |
Bemrist Breezhaler |
|
EU/1/20/1441 |
17.9.2024 |
||
|
16.9.2024 |
Binocrit |
|
EU/1/07/410 |
17.9.2024 |
||
|
16.9.2024 |
Enerzair Breezhaler |
|
EU/1/20/1438 |
17.9.2024 |
||
|
16.9.2024 |
Enhertu |
|
EU/1/20/1508 |
20.9.2024 |
||
|
16.9.2024 |
Irbesartan Teva |
|
EU/1/09/576 |
17.10.2024 |
||
|
16.9.2024 |
Ledaga |
|
EU/1/16/1171 |
18.9.2024 |
||
|
16.9.2024 |
Melatonin Neurim |
|
EU/1/22/1694 |
17.9.2024 |
||
|
16.9.2024 |
Tezspire |
|
EU/1/22/1677 |
17.9.2024 |
||
|
16.9.2024 |
Toviaz |
|
EU/1/07/386 |
17.9.2024 |
||
|
19.9.2024 |
Amsparity |
|
EU/1/19/1415 |
23.9.2024 |
||
|
19.9.2024 |
Arsenic Trioxide Accord |
|
EU/1/19/1398 |
23.9.2024 |
||
|
19.9.2024 |
Beovu |
|
EU/1/19/1417 |
23.9.2024 |
||
|
19.9.2024 |
CABOMETYX |
|
EU/1/16/1136 |
23.9.2024 |
||
|
19.9.2024 |
EDURANT |
|
EU/1/11/736 |
23.9.2024 |
||
|
19.9.2024 |
Epoetin alfa Hexal |
|
EU/1/07/411 |
23.9.2024 |
||
|
19.9.2024 |
Evrenzo |
|
EU/1/21/1574 |
24.9.2024 |
||
|
19.9.2024 |
GAVRETO |
|
EU/1/21/1555 |
26.9.2024 |
||
|
19.9.2024 |
Giapreza |
|
EU/1/19/1384 |
23.9.2024 |
||
|
19.9.2024 |
Imvanex |
|
EU/1/13/855 |
19.9.2024 |
||
|
19.9.2024 |
Ivabradine Accord |
|
EU/1/17/1190 |
23.9.2024 |
||
|
19.9.2024 |
Januvia |
|
EU/1/07/383 |
23.9.2024 |
||
|
19.9.2024 |
Lunsumio |
|
EU/1/22/1649 |
23.9.2024 |
||
|
19.9.2024 |
Mayzent |
|
EU/1/19/1414 |
23.9.2024 |
||
|
19.9.2024 |
Neparvis |
|
EU/1/16/1103 |
23.9.2024 |
||
|
19.9.2024 |
Opsumit |
|
EU/1/13/893 |
23.9.2024 |
||
|
19.9.2024 |
Orladeyo |
|
EU/1/21/1544 |
23.9.2024 |
||
|
19.9.2024 |
Paxlovid |
|
EU/1/22/1625 |
23.9.2024 |
||
|
19.9.2024 |
Recarbrio |
|
EU/1/19/1420 |
23.9.2024 |
||
|
19.9.2024 |
RINVOQ |
|
EU/1/19/1404 |
23.9.2024 |
||
|
19.9.2024 |
Rybelsus |
|
EU/1/20/1430 |
24.9.2024 |
||
|
19.9.2024 |
Synagis |
|
EU/1/99/117 |
23.9.2024 |
||
|
19.9.2024 |
Ziextenzo |
|
EU/1/18/1327 |
23.9.2024 |
||
|
25.9.2024 |
Kinpeygo |
|
EU/1/22/1657 |
30.9.2024 |
||
|
25.9.2024 |
Spevigo |
|
EU/1/22/1688 |
27.9.2024 |
||
|
25.9.2024 |
Stelara |
|
EU/1/08/494 |
26.9.2024 |
||
|
25.9.2024 |
Talmanco |
|
EU/1/16/1153 |
2.9.2024 |
||
|
25.9.2024 |
Talmanco |
|
EU/1/16/1153 |
26.9.2024 |
||
|
25.9.2024 |
Yuflyma |
|
EU/1/20/1513 |
27.9.2024 |
||
|
26.9.2024 |
Comirnaty |
|
EU/1/20/1528 |
26.9.2024 |
||
|
27.9.2024 |
Adrovance |
|
EU/1/06/364 |
3.10.2024 |
||
|
27.9.2024 |
Biopoin |
|
EU/1/09/565 |
2.10.2024 |
||
|
27.9.2024 |
Breyanzi |
|
EU/1/22/1631 |
30.9.2024 |
||
|
27.9.2024 |
Cometriq |
|
EU/1/13/890 |
30.9.2024 |
||
|
27.9.2024 |
Dabigatran etexilate Teva |
|
EU/1/23/1769 |
1.10.2024 |
||
|
27.9.2024 |
Fampyra |
|
EU/1/11/699 |
1.10.2024 |
||
|
27.9.2024 |
GONAL-f |
|
EU/1/95/001 |
1.10.2024 |
||
|
27.9.2024 |
Ivabradine Zentiva |
|
EU/1/16/1144 |
3.10.2024 |
||
|
27.9.2024 |
Lacosamide Adroiq |
|
EU/1/23/1732 |
2.10.2024 |
||
|
27.9.2024 |
MAVENCLAD |
|
EU/1/17/1212 |
30.9.2024 |
||
|
27.9.2024 |
Mylotarg |
|
EU/1/18/1277 |
30.9.2024 |
||
|
27.9.2024 |
Padcev |
|
EU/1/21/1615 |
30.9.2024 |
||
|
27.9.2024 |
Plerixafor Accord |
|
EU/1/22/1701 |
30.9.2024 |
||
|
27.9.2024 |
Shingrix |
|
EU/1/18/1272 |
30.9.2024 |
||
|
27.9.2024 |
Tenofovir disoproxil Viatris |
|
EU/1/16/1129 |
30.9.2024 |
||
|
27.9.2024 |
Tesavel |
|
EU/1/07/435 |
30.9.2024 |
||
|
27.9.2024 |
Tolucombi |
|
EU/1/13/821 |
3.10.2024 |
||
|
27.9.2024 |
Tyruko |
|
EU/1/23/1745 |
30.9.2024 |
||
|
27.9.2024 |
Vantavo |
|
EU/1/09/572 |
30.9.2024 |
||
|
27.9.2024 |
YERVOY |
|
EU/1/11/698 |
30.9.2024 |
||
|
30.9.2024 |
Myozyme |
|
EU/1/06/333 |
1.10.2024 |
— Údarú margaíochta a tharraingt siar (Airteagal 13 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle)
|
Dáta an chinnidh |
Ainm an táirge íocshláinte |
Sealbhóir an údaraithe margaíochta |
Uimhir na hiontrála sa Chlár Comhphobail |
Dáta an fhógra |
||
|
6.9.2024 |
Memantine LEK |
|
EU/1/13/826 |
10.9.2024 |
||
|
25.9.2024 |
Exviera |
|
EU/1/14/983 |
26.9.2024 |
||
|
25.9.2024 |
Viekirax |
|
EU/1/14/982 |
26.9.2024 |
||
|
27.9.2024 |
Gefitinib Mylan |
|
EU/1/18/1321 |
30.9.2024 |
— Údarú margaíochta a eisiúint (Airteagal 38 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle; Airteagal 5 de Rialachán (AE) 2019/6 ó Pharlaimint na hEorpa agus ón gComhairle): Glactha
|
Dáta an chinnidh |
Ainm an táirge íocshláinte |
ANI (an tAinm Neamhdhílseánaigh Idirnáisiúnta) |
Sealbhóir an údaraithe margaíochta |
Uimhir na hiontrála sa Chlár Comhphobail |
Foirm chógaisíochta |
An Cód CAT (an Cód Ceimiceach Teiripeach Anatamaíoch) |
Dáta an fhógra |
||
|
12.9.2024 |
Cepeloron |
spironolactone |
|
EU/2/24/321 |
Piolla inchoganta |
Pending |
13.9.2024 |
— Údarú margaíochta a mhodhnú (Airteagal 38 de Rialachán (CE) Uimh. 726/2004 ó Pharlaimint na hEorpa agus ón gComhairle; Airteagal 5 de Rialachán (AE) 2019/6 ó Pharlaimint na hEorpa agus ón gComhairle): Glactha
|
Dáta an chinnidh |
Ainm an táirge íocshláinte |
Sealbhóir an údaraithe margaíochta |
Uimhir na hiontrála sa Chlár Comhphobail |
Dáta an fhógra |
||
|
6.9.2024 |
Posatex |
|
EU/2/08/081 |
9.9.2024 |
||
|
6.9.2024 |
Profender |
|
EU/2/05/054 |
9.9.2024 |
||
|
12.9.2024 |
Rabitec |
|
EU/2/17/219 |
13.9.2024 |
||
|
19.9.2024 |
Brucellin Aquilon |
|
EU/2/22/291 |
25.9.2024 |
Aon duine ar mian leis féachaint ar an tuarascáil mheasúnaithe phoiblí maidir leis na táirgí íocshláinte atá i gceist agus na cinntí a bhaineann léi, iarrtar orthu teagmháil a dhéanamh le:
|
European Medicines Agency |
|
Domenico Scarlattilaan 6 |
|
1083 HS Amsterdam |
|
NETHERLANDS |
(1) IO L 136, 30.4.2004, lch. 1, ELI: https://data.europa.eu/eli/reg/2004/726/oj.
(2) IO L 4, 7.1.2019, lch. 43, ELI: https://data.europa.eu/eli/reg/2019/6/oj.
ELI: http://data.europa.eu/eli/C/2024/6277/oj
ISSN 1977-107X (electronic edition)